In February there was an abundance of funding raised by companies in the Biotech and Biopharma space. Within this blog, Invenia Group Consultant Katie Davis dives into  key findings, and the companies raising these funds. You can subscribe to monthly biotech funding updates over on LinkedIn to keep up to date with the ever-growing biotech market.

 

 

Acquisitions, spin-outs and expansions

Renovaro Biosciences Inc., a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, announced a definitive agreement to merge with BioSymetrics, an AI-driven drug discovery and biomarker identification company.

Singular Genomics announced closing of acquisition by Deerfield Management

Solventum announced sale of its purification & filtration business to Thermo Fisher Scientific for $4.1B

Maravai LifeSciences completed the acquisition of Officinae Bio’sDNA and RNA business

Ignite Proteomics announced the completed transfer of PLA code 0249U (originally issued to Theralink Technologies, Inc.) to Ignite. This milestone integrates the laboratory capabilities and IP for its proteomic breast cancer assay, with the associated AMA CPT code now listed on the Medicare CLFS and addressed by the Palmetto GBA MolDx “Proteomics Testing” article (A59636).

Bio-Rad Laboratories announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies

Biolog, Inc. purchased Anaerobe Systems, Inc., its third acquisition, becoming the knowledge leader in microbiology research and clinical sample prep

Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO with facilities in Belgium, Spain, the Netherlands, and Sweden, announced that it has successfully completed the acquisition of Catalent Pharma Solutions’s state-of-the-art drug product manufacturing facility in Somerset, New Jersey.

Moss Genomics announces private placement and agreement to acquire Ethereum, becoming Moss Ethereum

 

Legal updates

10x Genomics and Vizgensettled an intellectual property dispute over patents covering spatial transcriptomics technology. The suit was dismissed with prejudice.

Parse Biosciences announced that the USPTO’s Patent Trial and Appeal Board has invalidated all claims in three 10x Genomics patents, strengthening Parse’s position in single-cell innovation.

CareDx, Inc. announced District Court reversed jury decision in patent infringement case overturning prior $96 million verdict

Caltech sued Bio-Rad Laboratoriesfor allegedly infringing a patent related to multiplex PCR technology.

 

Collaborations and partnerships

MaxCyte, Inc. signs strategic platform license with TG Therapeutics to advance its autoimmune cell therapeutics programs

Vizgen announced multiple Certified Service Providers including Earlham Institute and Portrai Inc..

Basepair Inc and TrendBio Pty Ltd announce distribution agreement to enhance genomic research in Australia & New Zealand

GRAIL and Quest Diagnosticsannounced the initial phase of a program to improve provider access to GRAIL’s Galleri® MCED test. Providers can now order the Galleri test directly from GRAIL through the Quest Diagnostics connectivity system.

Sapio Sciences announced that LabConnect has selected Sapio LIMS to digitally transform research workflows, streamline sample tracking, and enhance data management.

GeneDxannounced its launch on Aura, Epic’s specialty diagnostics suite, offering advance genetic sequencing within health systems electronic health records to receive orders and send results.

The Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, aiming to generate an unprecedented one billion cell dataset to accelerate AI-driven breakthroughs in biology. Partners include 10x Genomics, Ultima Genomics , and top researchers.

Ultima Genomics expands global access to high-quality, low-cost DNA sequencing on the UG 100™ sequencing platform through partnerships with multiple premier genomic services providers. This includes include Broad Clinical Labs, Eurofins, Novogene, Psomagen and Ontario Institute of Cancer Research.

Alamar Biosciences, Inc. introduced its Certified Service Provider Program to expand access to NULISA technology for academic and biopharma researchers. Service providers include Biognosys, Banner Health, Emtherapro, Esya Labs, Frontage Labs, and Sapient.

Predictive Oncology teamed up with Tecan to enhance high-throughput drug screening, incorporating human tumor spheroids, automated imaging, and 3D analysis.

Antibodies.com and Cactus Communications partner to accelerate life science manuscript publication

Charles River Laboratories and Deciphex advanced their strategic collaboration, focusing on cutting-edge image management solutions and the development of AI-powered tools for toxicologic pathology.

Ginkgo Bioworks, Inc. partners with the European Health and Digital Executive Agency (HaDEA)in up to €24 million consortium project to deliver next-generation ‘agnostic diagnostics’ for respiratory viruses at the point of care.

Myriad Genetics announced multiple collaborations including with:

  • Gabbi to work together to increase access to hereditary cancer risk assessment tools
  • PATHOMIQ, Inc. to add Artificial Intelligence technology platform to its oncology portfolio
  • Lumea to enhance access to the Prolaris biomarker and MyRisk hereditary cancer tests through BxLink integration

Charles River Laboratories announces agreement with Singapore General Hospital to provide CGMP-compliant master cell banking and NGS-based services for use in cell line characterization.

Rancho BioSciences announced that Bristol Myers Squibb renewed membership for Phase 2 of the Single-Cell Data Science Consortium

Yemaachi Biotech launches the African Cancer Atlas, in partnership with Roche

Illumina and Broad Clinical Labswill collaborate to develop a 5 billion-cell atlas within three years using Illumina single-cell sequencing technologies.

Pillar Biosciences Incorporated and Hamilton Companypartner on NGS panel automation. They also partnered with GenomOncology to develop NGS-driven clinical decision support solution.

Foundation Medicine will collaborate with Sumitomo Pharma America, Inc. to develop a companion diagnostic to identify acute leukemia patients. They also partnered with Fulgent Geneticsto launch two new NGS-based germline tests in the US.

Tempus AI announced multiple collaboration including with:

BostonGene and BeiGene to identify actionable tumor-based biomarkers in mantle cell lymphoma (MCL) to guide precision medicine treatment approaches.

DNAstack announced the launch of the Canadian Platform for AI in Health, a consortium focused on improving patient outcomes by establishing national and international AI infrastructure for genomics and health. The consortium aims to streamline DNAstack’s Omics AI data-sharing software suite and to develop new Omics AI features and related products. Consortium members include Autism Speaks, Valence Digital, PacBio, and SickKids Foundation with co-investment from DIGITAL

 

single cell

 

Genomenon, Inc and Mirum Pharmaceuticals, Inc. partner to improve the awareness and diagnosis of cerebrotendinous xanthomatosis (CTX) through genetic data sharing.

Flatiron Health and Exact Sciences they have entered a strategic partnership to hasten the generation of real-world clinical evidence for Exact Sciences’ MRD test, Oncodetect.

Siemens Healthineers and ABL Diagnostics S.A have signed an agreement that will let ABL manufacture and commercialize a portfolio of PCR testing products that integrate technologies owned by Siemens.

Tasso, Inc. and ARUP Laboratories will join forces to offer biomarker testing services for clinical research using samples collected by participants at home.

Fore Genomics has entered into a strategic partnership with Inocras Inc. to offer improved pediatric and newborn health screening services.

TriLink BioTechnologies, part of Maravai LifeSciences partnered with Avantor to expand Nucleic Acid Solutions in Europe. They also signed a non-exclusive License and Supply Agreement with CDMO Aldevron to provide high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics.

DNAnexus expands relationship with Veeva Systems to advance global regulatory collaboration in the cloud.

Rapid Micro Biosystems announces global distribution and collaboration agreement with the Life Science business of Merck KGaA, Darmstadt, Germany

 

Product updates

MESO SCALE DIAGNOSTICS, LLC.introduced the QuickPlex Q60 MM instrument, offering 5 logs of dynamic range, attomolar sensitivity, and multiplexing with over 600 assays. It features high-performance technology, flexible assays, and minimal maintenance due to no microfluidics. With detection limits as low as 0.05 to 1 pg/mL, it delivers results in just 1 minute 23 seconds. The compact design (13” x 23” x 14”) makes it space-efficient. For this launch they have a special pricing program for Academic researchers.

Nature’s Toolbox, Inc. (NTx) a life sciences company developing next-generation platforms for RNA and protein manufacturing, announced the full commercial availability of NTxscribe®, a benchtop, continuous flow RNA in vitro transcription (IVT) and purification system that brings cost effective and scalable RNA manufacturing to the market.

Cancer researchers at BioTuring , an NVIDIA Inception member, unveiled a new AI model that rapidly generates single-cell resolution visualizations of cancerous tumors, enabling real-time insights into tumour dynamics, gene activation, and interactions between cancerous and immune cells.

Stellaromics Inc. unveiled new spatial biology platform, Pyxa. Based upon Stellaromics’ Starmap and Ribomap technologies, Pyxa promises to analyze both thin and thick tissue sections with subcellular resolution.

iconPCR_n6has launched the world’s first individually controlled, plate-based thermocycling technology, iconPCR™, marking a breakthrough in DNA amplification and NGSp workflows.

Paige announced an expansion of Paige PanCancer Detect, the first AI application capable of identifying cancer across more than 40 tissue and organ types.

Ramonaannounced the launch of the Vireo™, a live-cell imaging system designed to transform drug discovery. The Vireo leverages 24x miniaturized 4k video microscopes and real-time AI image processing to analyze every well in a 96-well plate across 5 channels in under 2 minutes – an order of magnitude faster than traditional solutions.

Alida Biosciencesannounced the full commercial launch of its EpiPlex™ platform, the first to concurrently detect and quantify multiple RNA modifications by short-read sequencing in addition to providing gene expression data.

Portal has launched the new Galaxy system. This high throughput instrument could potentially enable broader applications across cell engineering and drug discovery – expanding on the success of the Gateway device launched in early 2023.

Rocheunveiled at AGBT its groundbreaking sequencing by expansion (SBX) technology, combining advanced chemistry with a novel sensor module for ultra-rapid, high-throughput, and scalable sequencing. SBX encodes DNA or RNA sequences into Xpandomers, which provide clearer signals with minimal noise, enabling accurate single-molecule sequeoncing. This technology addresses key limitations of existing solutions, offering unprecedented speed, flexibility, and efficiency, making it ideal for a broad range of applications, particularly in understanding complex diseases like cancer and neurodegenerative conditions.

Alamar Biosciences, Inc. launches the NULISAqpcr™ Custom Assay Development Kit to advance the development of novel biomarker assays for clinical research

BioAro Inc. launches AI-driven PanOmiQ with ultrafast whole genome sequencing analysis technology

Metabolon, Inc. expanded its Integrated Bioinformatics Platform with new multiomics biomarker discovery capabilities, including predictive modeling, pathway analysis, and advanced data visualization tools.

Ultima Genomics announced the commercial launch of UG 100 Solaris at AGBT. UG 100 Solaris features new chemistry, software, and simplified workflows to significantly increase output and lower cost on the UG 100 sequencing platform.

PGxAIlaunched Vega, its latest AI model designed to help physicians and health systems tailor drug therapy based on individual genetic profiles.

Claret Biosciencehas launched its REALLY hg-rNONE kits for depletion and whole-blood RNA-seq. This library workflow for Illumina sequencing adds to the company’s REALLY line of RNA-seq products.

Bruker launched X4 POSEIDON™ Advanced X-Ray Microscope for three-dimensional microscopy in industrial and scientific applications. They also launched new mass spectrometry software:

  • DeutEx for hydrogen-deuterium exchange analysis, OmniScape 2025 for advanced sequencing and annotation
  • ProteoScape V.2025c with updated Spectronaut and GlycoScape
  • TwinScape, a cloud-based AI-enabled quality monitoring tool.

Avance Biosciences, Inc. registered with the CLIA program, expanding their clinical trial testing capabilities

Dovetail Genomicslaunched early access services for FFPE sample analysis, enabling structural variant detection and RNA profiling in oncology research.

Datar Cancer Genetics Limited unveils next generation multi-analyte, AI-powered decision support platform for personalized treatment of difficult-to-treat cancers.

Labcorp launched Plasma Complete™, a ctDNA-based liquid biopsy test for comprehensive genomic profiling in advanced solid tumors. This test helps oncologists personalize treatment decisions using a simple blood draw.

Opentrons Labworks Inc.has launched the Flex Proteomics Workstation, an automated system for common proteomics workflows, including preparing mass spectrometry (MS) samples.

Seonix Biolaunched SightScore, a clinical polygenic risk score testing service for glaucoma, in the US.

Lynx Dxhas launched its MyProstateScore 2.0 (MPS2) prostate cancer test kit for at-home collection of urine samples that are tested in the company’s Michigan laboratory.

seqWellis now providing early access to its new MosaiX Library Prep Kit for demanding applications in human population genomics such as whole-exome and whole-genome sequencing.

Parse Bioscienceslaunched the Evercode Whole Transcriptome Penta and Penta 384 single-cell RNA sequencing kits to profile 5 million cells and 384 samples in a single run.

BD Biosciences launches Omics-One Protein Panels to simplify and reduce costs for single-cell multiomics and CITE-seq studies:

  • Adaptive Protein Panel – 59-plex targeting key adaptive immune system markers
  • B-Cell Protein Panel – 30-plex for B-cell subtyping and activation states
  • T-Cell Protein Panel – 30-plex for T-cell subtyping and immune profiling

Yourgene Healthhas launched Iona Care+, a comprehensive noninvasive prenatal testing service, in the UK.

GeneDxhas launched the UltraRapid whole-genome sequencing test for comprehensive genomic insights for neonatal and pediatric patients in the NICU and PICU in as soon as two days.

Thermo Fisher Scientifichas launched the Invitrogen EVOS S1000 Spatial Imaging System, a widefield spectral imaging system that combines multiplex spectral fluorescence, transmitted brightfield, and color brightfield detection.

Devyserhas launched the Devyser Thlassemia v2 RUO NGS assay to screen for comprehensive genetic testing of alpha and beta thalassemia.

Aiforia Technologies secures IVDR certification, paving the way for expanded clinical portfolio in Europe

MRC Hollandgets CE-IVDR certification for multiple tests including for Spinal Muscular Atrophy, Breast & Ovarian Cancer Syndrome and Imprinting Disorders Test.

Qlucore gains CE-IVDR certification for pediatric leukemia testing software

Visby Medical gains FDA 510(k) clearance & CLIA waiver for POC respiratory panel

Natera’s MRD test receives MolDx coverage for lung cancer surveillance

bioMérieux gets Health Canada Approval for Respiratory & Sore Throat Panel. They also received FDA clearance for self-collected STI molecular test

ClearNote Health gains NYS DOH clearance for pancreatic cancer blood test

Targeted Genomics receives FDA clearance for DTC celiac disease genetic risk test

Abbott receives FDA clearance for self-collected STI Molecular test

 

 

If you’re a biotech startup looking for life science or biotech talent, or you’d like to learn more about our recruitment services, submit your vacancy and a recruitment consultant that specialises in your field will be in touch shortly.

Alternatively, are you seeking advice on your next move? I’m here to help. Register with us today to schedule a confidential discussion about your career prospects.